1-13 of 13
Li Li
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract B045: Ataxia telangiectasia- and Rad3-related kinase inhibitor (ATRi) camonsertib in combination with low dose gemcitabine in patients with solid tumors with DNA damage response (DDR) aberrations: Preclinical and Phase 1b results

Ezra Rosen, Timothy A Yap, Elisa Fontana, Elizabeth K Lee, Devalingam Mahalingam, Martin Højgaard, Niharika B Mettu, Gregory M Cote, Ruth Plummer, Ian M Silverman, Joseph D Schonhoft, Emeline Bacque, Adrian J Fretland, Gabriela Gomez, Danielle Ulanet, Kezhen Fei, Julia Yang, Maria Koehler, Anne Roulston, Li Li, Michal Zimmermann, Benedito A Carneiro, Stephanie Lheureux
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2023) 22 (12_Supplement): B045.
https://doi.org/10.1158/1535-7163.TARG-23-B045
Published: 01 December 2023
View article titled, Abstract B045: Ataxia telangiectasia- and Rad3-related kinase inhibitor (ATRi) camonsertib in combination with low dose gemcitabine in patients with solid tumors with DNA damage response (DDR) aberrations: Preclinical and Phase 1b results
Journal Articles

RP-3500: A Novel, Potent, and Selective ATR Inhibitor that is Effective in Preclinical Models as a Monotherapy and in Combination with PARP Inhibitors

Anne Roulston, Michal Zimmermann, Robert Papp, Alexander Skeldon, Charles Pellerin, Émilie Dumas-Bérube, Valerie Dumais, Stéphane Dorich, Lee D. Fader, Sara Fournier, Li Li, Marie-Eve Leclaire, Shou Yun Yin, Amandine Chefson, Hunain Alam, William Yang, Chloe Fugère-Desjardins, Sabrina Vignini-Hammond, Kathryn Skorey, Amina Mulani, Victoria Rimkunas, Artur Veloso, Martine Hamel, Rino Stocco, Yael Mamane, Zuomei Li, Jordan T.F. Young, Michael Zinda, W. Cameron Black
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2022) 21 (2): 245–256.
https://doi.org/10.1158/1535-7163.MCT-21-0615
Published: 01 February 2022
View article titled, RP-3500: A Novel, Potent, and Selective ATR Inhibitor that is Effective in Preclinical Models as a Monotherapy and in Combination with PARP Inhibitors
Open the PDF for RP-3500: A Novel, Potent, and Selective ATR Inhibitor that is Effective in Preclinical Models as a Monotherapy and in Combination with PARP Inhibitors in another window
Includes: Supplementary data
Journal Articles

Abstract P054: RP-3500: A novel, potent and selective ATR inhibitor that is effective in pre-clinical models as a monotherapy and in combination with PARP inhibitors

Anne Roulston, Michal Zimmerman, Robert Papp, Alex Skeldon, Charles Pellerin, Émilie Dumas-Bérube, Valerie Dumais, Stephane Dorich, Sara Fournier, Li Li, Marie-Ève Leclaire, Shou Yun Yin, Amandine Chefson, Hunain Alam, William Yang, Chloe Fugère-Desjardins, Sabrina Hammond, Kathryn Skorey, Amina Mulani, Victoria Rimkunas, Artur Veloso, Martine Hamel, Rino Stocco, Yael Mamane, Zuomei Li, Jordan Young, Mike Zinda, Cameron Black
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2021) 20 (12_Supplement): P054.
https://doi.org/10.1158/1535-7163.TARG-21-P054
Published: 01 December 2021
View article titled, Abstract P054: RP-3500: A novel, potent and selective ATR inhibitor that is effective in pre-clinical models as a monotherapy and in combination with PARP inhibitors
Journal Articles

Real-world Experience of Olaparib Treatment in Patients with Ovarian Cancer: A Chinese Multicenter Study

Hong Zheng, Yunong Gao, Hongyan Guo, Li Li, Qingshui Li, Heng Cui, An Lin, Lixin Sun, Yuanjing Hu, Shan Kang, Wei Duan, Lingya Pan, Shuzhen Wang, Yingjie Yang, Yunxia Li, Weimin Kong, Yang Xiang, Xiaofei Tian, Bin Ling, Chunfang Ha, Wenpei Bai
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2021) 20 (9): 1735–1742.
https://doi.org/10.1158/1535-7163.MCT-20-1064
Published: 01 September 2021
View article titled, Real-world Experience of Olaparib Treatment in Patients with Ovarian Cancer: A Chinese Multicenter Study
Open the PDF for Real-world Experience of Olaparib Treatment in Patients with Ovarian Cancer: A Chinese Multicenter Study in another window
Journal Articles

Sulindac Modulates the Response of Proficient MMR Colorectal Cancer to Anti–PD-L1 Immunotherapy

Bin Yi, Hao Cheng, Dorota Wyczechowska, Qingzhao Yu, Li Li, Augusto C. Ochoa, Adam I. Riker, Yaguang Xi
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2021) 20 (7): 1295–1304.
https://doi.org/10.1158/1535-7163.MCT-20-0934
Published: 01 July 2021
View article titled, Sulindac Modulates the Response of Proficient MMR Colorectal Cancer to Anti–PD-L1 Immunotherapy
Open the PDF for Sulindac Modulates the Response of Proficient MMR Colorectal Cancer to Anti–PD-L1 Immunotherapy in another window
Includes: Supplementary data
Journal Articles

Co-targeting Bulk Tumor and CSCs in Clinically Translatable TNBC Patient-Derived Xenografts via Combination Nanotherapy

Andrew Sulaiman, Sarah McGarry, Sara El-Sahli, Li Li, Jason Chambers, Alexandra Phan, Marceline Côté, Greg O. Cron, Tommy Alain, Yevgeniya Le, Seung-Hwan Lee, Sheng Liu, Daniel Figeys, Suresh Gadde, Lisheng Wang
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (10): 1755–1764.
https://doi.org/10.1158/1535-7163.MCT-18-0873
Published: 01 October 2019
View article titled, Co-targeting Bulk Tumor and CSCs in Clinically Translatable TNBC Patient-Derived Xenografts via Combination Nanotherapy
Open the PDF for Co-targeting Bulk Tumor and CSCs in Clinically Translatable TNBC Patient-Derived Xenografts via Combination Nanotherapy in another window
Includes: Supplementary data
Journal Articles

Targeting Phosphatidylserine with Calcium-Dependent Protein–Drug Conjugates for the Treatment of Cancer

Ran Li, Srinivas Chiguru, Li Li, Dongyoung Kim, Ramraj Velmurugan, David Kim, Siva Charan Devanaboyina, Hong Tian, Alan Schroit, Ralph P. Mason, Raimund J. Ober, E. Sally Ward
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2018) 17 (1): 169–182.
https://doi.org/10.1158/1535-7163.MCT-17-0092
Published: 01 January 2018
View article titled, Targeting Phosphatidylserine with Calcium-Dependent Protein–Drug Conjugates for the Treatment of Cancer
Open the PDF for Targeting Phosphatidylserine with Calcium-Dependent Protein–Drug Conjugates for the Treatment of Cancer in another window
Includes: Supplementary data
Journal Articles

Selumetinib Attenuates Skeletal Muscle Wasting in Murine Cachexia Model through ERK Inhibition and AKT Activation

Yang Quan-Jun, Huo Yan, Han Yong-Long, Wan Li-Li, Li Jie, Huang Jin-Lu, Lu Jin, Chen Peng-Guo, Gan Run, Guo Cheng
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2017) 16 (2): 334–343.
https://doi.org/10.1158/1535-7163.MCT-16-0324
Published: 02 February 2017
View article titled, Selumetinib Attenuates Skeletal Muscle Wasting in Murine Cachexia Model through ERK Inhibition and AKT Activation
Open the PDF for Selumetinib Attenuates Skeletal Muscle Wasting in Murine Cachexia Model through ERK Inhibition and AKT Activation in another window
Journal Articles

Preclinical Evaluation of a Novel Orally Available SRC/Raf/VEGFR2 Inhibitor, SKLB646, in the Treatment of Triple-Negative Breast Cancer

Ming-Wu Zheng, Chun-Hui Zhang, Kai Chen, Mei Huang, Ya-Ping Li, Wan-Ting Lin, Rong-Jie Zhang, Lei Zhong, Rong Xiang, Lin-Li Li, Xin-Yu Liu, Yu-Quan Wei, Sheng-Yong Yang
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2016) 15 (3): 366–378.
https://doi.org/10.1158/1535-7163.MCT-15-0501
Published: 06 March 2016
View article titled, Preclinical Evaluation of a Novel Orally Available SRC/Raf/VEGFR2 Inhibitor, SKLB646, in the Treatment of Triple-Negative Breast Cancer
Open the PDF for Preclinical Evaluation of a Novel Orally Available SRC/Raf/VEGFR2 Inhibitor, SKLB646, in the Treatment of Triple-Negative Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Genome-Wide Identification of a Methylation Gene Panel as a Prognostic Biomarker in Nasopharyngeal Carcinoma

Wei Jiang, Na Liu, Xiao-Zhong Chen, Ying Sun, Bin Li, Xian-Yue Ren, Wei-Feng Qin, Ning Jiang, Ya-Fei Xu, Ying-Qin Li, Jian Ren, William CS Cho, Jing-Ping Yun, Jing Zeng, Li-Zhi Liu, Li Li, Ying Guo, Hai-Qiang Mai, Mu-Sheng Zeng, Tie-Bang Kang, Wei-Hua Jia, Jian-Yong Shao, Jun Ma
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12): 2864–2873.
https://doi.org/10.1158/1535-7163.MCT-15-0260
Published: 06 December 2015
View article titled, Genome-Wide Identification of a Methylation Gene Panel as a Prognostic Biomarker in Nasopharyngeal Carcinoma
Open the PDF for Genome-Wide Identification of a Methylation Gene Panel as a Prognostic Biomarker in Nasopharyngeal Carcinoma in another window
Includes: Supplementary data
Journal Articles

Molecular Pharmacology and Antitumor Activity of PHT-427, a Novel Akt/Phosphatidylinositide-Dependent Protein Kinase 1 Pleckstrin Homology Domain Inhibitor

Emmanuelle J. Meuillet, Song Zuohe, Robert Lemos, Nathan Ihle, John Kingston, Ryan Watkins, Sylvestor A. Moses, Shuxing Zhang, Lei Du-Cuny, Roy Herbst, Jörg J. Jacoby, Li Li Zhou, Ali M. Ahad, Eugene A. Mash, D. Lynn Kirkpatrick, Garth Powis
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2010) 9 (3): 706–717.
https://doi.org/10.1158/1535-7163.MCT-09-0985
Published: 09 March 2010
View article titled, Molecular Pharmacology and Antitumor Activity of PHT-427, a Novel Akt/Phosphatidylinositide-Dependent Protein Kinase 1 Pleckstrin Homology Domain Inhibitor
Open the PDF for Molecular Pharmacology and Antitumor Activity of PHT-427, a Novel Akt/Phosphatidylinositide-Dependent Protein Kinase 1 Pleckstrin Homology Domain Inhibitor in another window
Journal Articles

Involvement of base excision repair in response to therapy targeted at thymidylate synthase

Li Li, Sondra H. Berger, Michael D. Wyatt
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2004) 3 (6): 747–753.
https://doi.org/10.1158/1535-7163.747.3.6
Published: 21 June 2004
View article titled, Involvement of base excision repair in response to therapy targeted at thymidylate synthase
Open the PDF for Involvement of base excision repair in response to therapy targeted at thymidylate synthase in another window
Journal Articles

Induction of Apoptosis in Mesothelioma Cells by Antisurvivin Oligonucleotides

Chunyao Xia, Zhidong Xu, Xiaocheng Yuan, Kazutsugu Uematsu, Liang You, Kai Li, Li Li, Frank McCormick, David M. Jablons
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2002) 1 (9): 687–694.
Published: 01 July 2002
View article titled, Induction of Apoptosis in Mesothelioma Cells by Antisurvivin Oligonucleotides
Open the PDF for Induction of Apoptosis in Mesothelioma Cells by Antisurvivin Oligonucleotides in another window